outpatients
Item
male and female outpatients
boolean
C0029921 (UMLS CUI [1])
age and asthma
Item
aged 6 to 18 with a clinical diagnosis of bronchial asthma with a duration of at least 6 months before the first visit and with current history of moderate persistent asthma
boolean
C0001779 (UMLS CUI [1])
C0004096 (UMLS CUI [2])
C1960047 (UMLS CUI [3])
sensitive to house dust mites
Item
sensitive to house dust mites as shown by positive skin-prick tests to dermatophagoides pteronyssinus or dermatophagoides farinae
boolean
C0020517 (UMLS CUI [1,1])
C3539110 (UMLS CUI [1,2])
C0430561 (UMLS CUI [2])
spirometry, whole body plethysmography and interrupter technique
Item
to become eligible for the active treatment period, patients and their parents were required to do reproducible spirometry, whole body plethysmography and interrupter technique.
boolean
C0037981 (UMLS CUI [1])
C0032224 (UMLS CUI [2])
fev1
Item
in order to be included in the study the patients had to have a resting fev1 of more or equal 70%.
boolean
C0748133 (UMLS CUI [1])
exclusion
Item
study exclusions included:
boolean
C2828389 (UMLS CUI [1])
respiratory tract infection and acute sinus disease requiring antibiotic treatment
Item
active upper respiratory tract infection within 3 weeks before the study and acute sinus disease requiring antibiotic treatment within 1 month before the study
boolean
C0035243 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0037199 (UMLS CUI [2])
C0003232 (UMLS CUI [3])
intubation
Item
previous intubation
boolean
C0021925 (UMLS CUI [1])
asthma hospitalisation
Item
asthma hospitalisation during the 3 months before the first visit.
boolean
C0019993 (UMLS CUI [1,1])
C0004096 (UMLS CUI [1,2])
comorbidity limiting study protocol
Item
additional criteria were other clinically significant pulmonary, hematologic, hepatic, gastrointestinal, renal, endocrine, neurologic, cardiovascular, and/or psychiatric diseases or malignancy that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator.
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
beta-blockers, astamizole, oral corticosteroids
Item
excluded medications were β-blockers (eye drops included), astemizole within 3 months, or oral corticosteroids within 1 month before the first visit.
boolean
C0304516 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
immunotherapy
Item
patients who were receiving immunotherapy were also excluded.
boolean
C0021083 (UMLS CUI [1])